COMP <GO>
VMD vs LLY // RETURN ON INVESTED CAPITAL (ROIC)
Viemed Healthcare Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: VMD 3
— LLY 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: LLY
LAST: $9.95 (-0.40%) • MKT CAP: $379.0M
roic
13.00%
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
roic
32.36%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VMD VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VMD | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 57.50% | 83.64% | -26.14 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 13.00% | 32.36% | -19.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.6x | 36.4x | -29.82 | VMD | /valuation <GO> |
| Free Cash Flow Yield | 3.15% | 2.30% | +0.85 | VMD | /fcf-yield <GO> |
| Operating Margin | 8.50% | 40.21% | -31.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | 5.70% | 31.90% | -26.20 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 20.50% | 45.51% | -25.01 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.59 | 9.29 | -2.70 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.1 | 66.6 | -13.49 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.7x | 26.3x | -5.55 | VMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $379.0M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VMD REV | LLY REV | VMD GROSS % | LLY GROSS % | VMD FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $270.3M | $65.18B | 57.5% | 83.0% | $11.9M | $16.81B |
| FY 2024 | $224.3M | $45.04B | 59.4% | 81.3% | $1.3M | $8.82B |
| FY 2023 | $183.0M | $34.12B | — | 79.3% | $45.2M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VMD // BETA —
LLY // BETA 0.51